Year : 2016 | Volume
: 17 | Issue : 4 | Page : 129--135
Statin induced regression of cardiomyopathy trial: A randomized, placebo-controlled double-blind trial
Ahmad Hersi1, J Peter Giannoccaro2, Andrew Howarth2, Derek Exner2, Sarah Weeks2, Ingo Eitel2, R Cameron Herman2, Henry Duff2, Debbie Ritchie2, Maureen Mcrae2, Robert Sheldon2
1 Department of Cardiac Sciences, King Saud University Medical City, College of Medicine, Riyadh, Kingdom of Saudi Arabia
2 Department of Cardiac Sciences, Libin Cardiovascular Institue of Alberta, University of Calgary, Calgary, Alberta, Canada
Background: Hypertrophic cardiomyopathy (HCM), characterized by a thickened, fibrotic myocardium, remains the most common cause of sudden cardiac death in young adults. Based on animal and clinical data, we hypothesized that atorvastatin would induce left ventricular (LV) mass regression.
Methods: Statin Induced Regression of Cardiomyopathy Trial (SIRCAT) was a randomized, placebo-controlled study. The primary endpoint was change in LV mass measured by cardiac magnetic resonance imaging 12 months after treatment with once-daily atorvastatin 80 mg or placebo. A key secondary endpoint was diastolic dysfunction measured echocardiographically by transmitral flow velocities. SIRCAT is registered with www.clinicaltrials.gov (NCT00317967).
Results: Of 222 screened patients, 22 were randomized evenly to atorvastatin and placebo. The mean age was 47 ± 10 years, and 15 (68%) were male. All subjects completed the protocol. At baseline, LV masses were 197 ± 76 g and 205 ± 82 g in the placebo and atorvastatin groups, respectively. After 12 months treatment, the LV masses in the placebo and atorvastatin groups were 196 ± 80 versus 206 ± 92 g (P = 0.80), respectively. Echocardiographic indices were not different in the two groups at baseline. After 12 months, diastolic dysfunction as assessed using transmitral flow velocities E/E', A/A', and peak systolic mitral velocity showed no benefit from atorvastatin.
Conclusions: In patients with HCM, atorvastatin did not cause LV mass regression or improvements in LV diastolic function.
Libin Cardiovascular Institute of Alberta, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta T2N 4N1
|How to cite this article:|
Hersi A, Giannoccaro J P, Howarth A, Exner D, Weeks S, Eitel I, Herman R C, Duff H, Ritchie D, Mcrae M, Sheldon R. Statin induced regression of cardiomyopathy trial: A randomized, placebo-controlled double-blind trial.Heart Views 2016;17:129-135
|How to cite this URL:|
Hersi A, Giannoccaro J P, Howarth A, Exner D, Weeks S, Eitel I, Herman R C, Duff H, Ritchie D, Mcrae M, Sheldon R. Statin induced regression of cardiomyopathy trial: A randomized, placebo-controlled double-blind trial. Heart Views [serial online] 2016 [cited 2017 Mar 27 ];17:129-135
Available from: http://www.heartviews.org/article.asp?issn=1995-705X;year=2016;volume=17;issue=4;spage=129;epage=135;aulast=Hersi;type=0